Moreover, comparing the levels of these biomarkers across various neurodegenerative diseases may enhance the diagnostic accuracy for PD, particularly considering that tau fragments and C1M levels may escalate during neurodegenerative processes. This evidence concerns the gene MAPT and Parkinson disease.